Valuation: Glenmark Pharmaceuticals Limited

Market Cap 75TCr 807.04Cr 735.05Cr 677.31Cr 616.1Cr 1.16TCr 1.21TCr 8.24TCr 3.28TCr 41TCr 3.03TCr 2.96TCr 1,28100Cr P/E 2027 *
33.4x
P/E 2028 * 27.2x
Enterprise Value 74TCr 793.81Cr 723Cr 666.2Cr 606Cr 1.14TCr 1.19TCr 8.11TCr 3.22TCr 40TCr 2.98TCr 2.92TCr 1,26000Cr EV / Sales 2027 *
4.34x
EV / Sales 2028 * 3.86x
Free-Float
51.04%
Yield 2027 *
0.16%
Yield 2028 * 0.15%
1 day+1.51%
1 week-0.44%
Current month+15.20%
1 month+19.81%
3 months+17.87%
6 months+10.06%
Current year+30.11%
1 week 2,600.2
Extreme 2600.2
2,691.5
1 month 2,101.6
Extreme 2101.6
2,714
Current year 1,842
Extreme 1842
2,714
1 year 1,825.1
Extreme 1825.1
2,714
3 years 761
Extreme 761
2,714
5 years 348.5
Extreme 348.5
2,714
10 years 161.65
Extreme 161.65
2,714
Manager TitleAgeSince
Chief Executive Officer 57 01/01/2000
Director of Finance/CFO 54 27/05/2025
President - 15/09/2023
Director TitleAgeSince
Director/Board Member 58 -
Chairman 57 12/05/2011
Director/Board Member 86 14/08/2009
Change 5-day change 1-year change 3-year change Capi.($)
+1.51%-0.44%+43.85%+241.26% 788.24Cr
-0.30%-5.62%+28.35%+127.66% 1,20400Cr
+1.25%-4.60%+33.56%+80.57% 64TCr
+0.94%-2.80%+22.88%+106.94% 50TCr
-0.60%-2.39%+27.92%+67.00% 38TCr
+0.69%-9.00%+40.68%+31.42% 33TCr
+0.41%-4.81%+24.99%+51.91% 28TCr
+0.81%-3.72%-1.35%+30.72% 27TCr
-0.15%-6.73%+27.23%+64.15% 24TCr
-0.06%-0.91%+29.95%+120.58% 21TCr
Average +0.80%-4.15%+27.81%+92.22% 41TCr
Weighted average by Cap. +0.62%-4.70%+27.28%+88.61%

Financials

2027 *2028 *
Net sales 17TCr 182.92Cr 166.61Cr 153.52Cr 139.65Cr 261.98Cr 275.34Cr 1.87TCr 742.61Cr 9.25TCr 686.33Cr 671.86Cr 29TCr 19TCr 203.09Cr 184.98Cr 170.45Cr 155.04Cr 290.87Cr 305.7Cr 2.07TCr 824.5Cr 10TCr 762.01Cr 745.95Cr 32TCr
Net income 2.2TCr 24Cr 22Cr 20Cr 18Cr 34Cr 36Cr 242.25Cr 96Cr 1.2TCr 89Cr 87Cr 3.76TCr 2.74TCr 30Cr 27Cr 25Cr 23Cr 42Cr 44Cr 301.73Cr 119.92Cr 1.49TCr 110.83Cr 108.5Cr 4.69TCr
Net Debt -1.23TCr -13Cr -12Cr -11Cr -10Cr -19Cr -20Cr -135.15Cr -54Cr -669.24Cr -50Cr -49Cr -2.1TCr -2.17TCr -23Cr -21Cr -20Cr -18Cr -34Cr -35Cr -239.53Cr -95Cr -1.19TCr -88Cr -86Cr -3.72TCr
Projected Income Statement - Annual - Glenmark Pharmaceuticals Limited
Logo Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Employees
16,946
Date Price Change Volume
20/26/20 ₹2,648.00 +1.51% 5,40,171
19/26/19 ₹2,608.50 -1.42% 3,92,816
18/26/18 ₹2,646.10 +1.16% 10,88,198
17/26/17 ₹2,615.80 -0.65% 2,92,746
16/26/16 ₹2,632.90 -0.27% 3,51,491
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - Glenmark Pharmaceuticals Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
2,648.00INR
Average target price
2,703.09INR
Spread / Average Target
+2.08%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Glenmark Pharmaceuticals Limited
  1. Stock Market
  2. Stocks
  3. GLENMARK Stock